VK2735: Phase 2 trial results for oral VK2735 are expected in the second half of 2025
Retatrutide represents the next evolution in metabolic treatment, offering what scientists describe as a triple-action approach that could potentially deliver even more impressive results than current medications
Heres what early studies have shown: Pancreatitis: Reported in about 0.4% Gallbladder problems: Seen in about 1.1% , with no cases in the placebo group Heart rhythm changes: Reported more often with retatrutide ( about 6% vs 3% with placebo ) Liver enzyme increases: Rare (around 1% ), with overall liver health markers staying stable While these serious side effects were uncommon, theyre still important to keep in mind
DENVER, May 7, 2026 (Newswire.com) - Medical Disclaimer: This advertorial is for informational purposes only and does not constitute medical advice, a treatment recommendation, or a guarantee that any prescription will be issued
This evening is designed to give guests a clear, practical understanding of how GLP-1 medications work, what results may be possible, what risks or side effects to consider, and what type of medical guidance is important throughout treatment
HRQoL was assessed with the Pediatric Quality of Life Inventory (PedsQL)
